Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by investment analysts at Panmure Gordon in a note issued to investors on Wednesday. They currently have a GBX 4,400 ($73.02) price objective on the stock. Panmure Gordon’s target price would suggest a potential downside of 3.11% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 28th. They now have a GBX 4,400 ($73.02) price target on the stock. Separately, analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, August 21st. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, August 21st. They now have a GBX 4,000 ($66.38) price target on the stock. Six analysts have rated the stock with a sell rating, seventeen have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of GBX 4,062.28 ($67.41).

Shares of AstraZeneca plc (LON:AZN) opened at 4568.50 on Wednesday. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00. The stock has a 50-day moving average of GBX 4334.24 and a 200-day moving average of GBX 4242.. The company’s market cap is £57.700 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.